MedTrace Logo

Biomarkers for Chemotherapy Associated Neurotoxicity

NCT05280262 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-03-15

No results posted yet for this study

Summary

To assess if biomarkers can be used to predict early treatment related neurotoxicity in patients with Acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) and to inform development of novel interventions.

Conditions

  • Chemotherapy-Related Cognitive Impairment

Interventions

DIAGNOSTIC_TEST

CogState Test

Computerized cognitive testing which provides a score/measurement of distinct cognitive functions

Sponsors & Collaborators

  • NHS Greater Glasgow and Clyde

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05280262 on ClinicalTrials.gov